Secondary Logo

Institutional members access full text with Ovid®

RETINAL VASCULITIS ASSOCIATED WITH EPSTEIN–BARR VIRUS INFECTION, A CASE REPORT

Victor, Andi A., MD, PhD*,†; Sukmana, Nanang, MD

Retinal Cases and Brief Reports: October 2018 - Volume 12 - Issue 4 - p 314–317
doi: 10.1097/ICB.0000000000000508
Case Report
Buy

Purpose: To report a case of retinal vasculitis associated with Epstein–Barr virus infection.

Methods: Case report.

Results: A 26-year-old woman came with blurry vision. Funduscopy illustrated vasculitis with frosted branch-like appearance. The patient was treated with systemic acyclovir and topical steroid. Circulating polymerase chain reaction was positive for Epstein–Barr virus antibodies. Two months of treatment resolved the clinical manifestations.

Conclusion: Epstein–Barr infection should be considered as the etiology of retinal vasculitis with similar clinical manifestations.

A case report illustrated retinal vasculitis associated with Epstein–Barr virus in a 26-year-old woman. Funduscopy revealed frosted branch-like vasculitis along with macular edema and exudate. The combination of systemic acyclovir and topical steroid was given and resolved the manifestations in 2 months.

*Vitreo-Retinal Division, Department of Ophthalmology, Faculty of Medicine, University of Indonesia, Dr. Cipto Mangunkusumo National General Hospital, Jakarta, Indonesia;

Prof. Dr. Isak Salim Aini Eye Hospital, Jakarta, Indonesia; and

Division of Clinical Allergy and Immunology, Department of Internal Medicine, Faculty of Medicine, University of Indonesia, Dr. Cipto Mangunkusumo National General Hospital, Jakarta, Indonesia.

Reprint requests: Andi A. Victor, MD, PhD, Vitreoretinal Division, Department of Ophthalmology, Faculty of Medicine, University of Indonesia, Cipto Mangunkusumo Hospital, Jl. Diponegoro No. 71, Centre of Jakarta, DKI Jakarta 10320, Indonesia; e-mail: arvimadao@yahoo.com

None of the authors has any financial/conflicting interests to disclose.

© 2018 by Ophthalmic Communications Society, Inc.